A Randomized Clinical Trial of Intravenous Methylprednisolone With 2 Protocols in Patients With Graves Orbitopathy
The Journal of Clinical Endocrinology & Metabolism · 2023
DOI: 10.1210/clinem/dgad476 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2023. Verfasst von Zhangfang Li und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology and Metabolism, The Third Affiliated Hospital of Southern Medical University, Guangzhou, Guangdong, China. Hauptthemen laut MEDLINE: Methylprednisolone, Graves Ophthalmopathy. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 35 Literaturangaben. Gefördert von: Southern Medical University, Guangdong Science and Technology Plan Project, China Health Promotion Foundation Thyroid Research Project for Young and Middle-aged Doctors.
Abstract (Originalsprache)
Context
Intravenous glucocorticoid (IVGC) is an accessible and affordable treatment for Graves orbitopathy (GO); the 4.5-g protocol is well studied, but many details of treatment protocols need to be clarified.
Objective
To compare the efficacy and safety of weekly and monthly protocol of IVGC in GO.
Methods
A prospective, randomized, observer-masked, single-center clinical trial, followed up to week 24, at the third affiliated hospital of Southern Medical University; 58 patients with active and moderate to severe GO, aged 18-60 years old, who had not received relevant treatment were included. The intervention was weekly protocol or monthly protocol of IVGC; both received a cumulative dose of methylprednisolone 4.5 g and had a duration of 12 weeks. The overall effective rate, improvement of quality of life (QOL) and signal intensity ratio (SIR) were measured.
Results
There was no significant difference in the effective rate between the 2 groups at week 12 and week 24 (86.21% vs 72.41%, P = .195; 86.21% vs 82.61%, P = .441), there was no significant difference in the improvement of clinical activity score, exophthalmos, soft tissue involvement, diplopia, and QOL. At week 24, the mean SIR and maximum SIR of the 2 groups were lower than those before treatment, and there were no statistically significant difference between the 2 groups. There was no significant difference in the incidence of adverse events between the 2 groups (31.03% vs 27.59%, P = .773).
Conclusion
The efficacy and safety of the 2 protocols are comparable; the monthly protocol could be used as an alternative to the weekly protocol.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Endocrinology and Metabolism, The Third Affiliated Hospital of Southern Medical University, Guangzhou, Guangdong, China.
- Department of Endocrinology and Metabolism, Shunde Hospital, Southern Medical University (The First People's Hospital of Shunde), Foshan, Guangdong, China.
- Department of Endocrinology, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China.
ORCID-Profile: Zhangfang Li, Yaosheng Luo, Chenzhong Li, Tong Zhang, Jie Shen
Förderung
- Southern Medical University
- Guangdong Science and Technology Plan Project
- China Health Promotion Foundation Thyroid Research Project for Young and Middle-aged Doctors
- Guangdong Province key Field Research and Development Plan Project
Zitieren
APA
Li, Z., Luo, Y., Huang, Q., Chen, Z., Song, D., Pan, D., Hu, S., Jiang, W., Cai, Q., Feng, X., Zhang, Q., Weng, C., Zhong, Q., Zhao, T., Li, C., Zhang, T., & Shen, J. (2023). A Randomized Clinical Trial of Intravenous Methylprednisolone With 2 Protocols in Patients With Graves Orbitopathy. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgad476
Vancouver
Li Z, Luo Y, Huang Q, Chen Z, Song D, Pan D, et al. A Randomized Clinical Trial of Intravenous Methylprednisolone With 2 Protocols in Patients With Graves Orbitopathy. The Journal of Clinical Endocrinology & Metabolism. 2023. doi:10.1210/clinem/dgad476
BibTeX
@article{Li2023,
author = {Li, Zhangfang and Luo, Yaosheng and Huang, Quandi and Chen, Zhi and Song, Dandan and Pan, Daoyan and Hu, Shidi and Jiang, Wei and Cai, Qiuyue and Feng, Xiaoting and Zhang, Qing and Weng, Chanyan and Zhong, Qiang and Zhao, Tongfeng and Li, Chenzhong and Zhang, Tong and Shen, Jie},
title = {A Randomized Clinical Trial of Intravenous Methylprednisolone With 2 Protocols in Patients With Graves Orbitopathy},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2023},
doi = {10.1210/clinem/dgad476}
}
EUVIMED